Illumina, Inc. (ILMN) Stock Price & Analysis
Illumina, Inc. (ILMN) rose 1.26% to USD 160.03 as of June 9, 2026 at 22:41 UTC, according to Nexqual real-time market data.
ILMN last closed at USD 158.04; the session ranged USD 155.58–161.12 on volume of 1,408,606 shares. Market capitalization is $24.21B, with a 52-week range of USD 85–177.22 (NMS). Source: Nexqual, June 9, 2026 at 22:41 UTC.
Key Statistics (as of June 9, 2026 at 22:41 UTC)
| Price | USD 160.03 |
|---|---|
| Change | ▲ 1.26% (up) |
| Previous Close | USD 158.04 |
| Open | USD 158.45 |
| Day Range | USD 155.58 – 161.12 |
| 52-Week Range | USD 85 – 177.22 |
| Volume | 1,408,606 shares |
| Market Cap | $24.21B |
| Exchange | NMS |
Technical Analysis (ILMN)
Nexqual's technical model rates ILMN "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 22:41 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.18 (neutral) |
| vs SMA50 | Above (USD 139.34) |
| MACD | 7.29 (positive) |
Analyst Ratings (ILMN)
Wall Street analysts rate ILMN "Buy" based on 18 analysts, with a mean price target of USD 143.83 (range USD 95–180), per Nexqual as of June 9, 2026 at 22:41 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 143.83 |
| High Target | USD 180 |
| Low Target | USD 95 |
| Buy / Hold / Sell | 10 / 5 / 4 |
Earnings (ILMN)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.22 |
| Revenue Estimate | $1.13B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.15 vs est 1.06 ▲ beat |
| 2025-12-31 | USD 1.35 vs est 1.23 ▲ beat |
| 2025-09-30 | USD 1.34 vs est 1.17 ▲ beat |
| 2025-06-30 | USD 1.19 vs est 1.01 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Financials & Fundamentals (ILMN)
| Total Revenue | $4.39B |
|---|---|
| Revenue Growth (YoY) | +4.80% |
| Gross Margin | +68.29% |
| Operating Margin | +18.33% |
| Profit Margin | +19.42% |
| ROE | +33.82% |
| Debt / Equity | 95.07 |
| Current Ratio | 1.75 |
| Total Cash | $1.16B |
| Total Debt | $2.54B |
| Free Cash Flow | $845.63M |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Financial Health Score (ILMN)
Nexqual rates Illumina, Inc.'s overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:41 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 68%, operating 18% |
| Balance Sheet | Mixed — $1.16B cash vs $2.54B debt |
| Cash Flow | Strong — FCF $846M, 19% margin |
| Efficiency | Strong — ROE 34%, ROA 8.7% |
Ownership (ILMN)
| Insider Ownership | +0.20% |
|---|---|
| Institutional Ownership | +106.51% |
| Shares Outstanding | 151.30M |
| Float | 148.03M |
| Short % of Float | +8.11% |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
Leadership (ILMN)
Illumina, Inc. is led by Jacob Thaysen (age 50), CEO, Interim Chief Commercial Officer & Director, per Nexqual as of June 9, 2026 at 22:41 UTC.
| CEO, Interim Chief Commercial Officer & Director | Jacob Thaysen (age 50) |
|---|---|
| Chief Financial Officer | Ankur Dhingra (age 49) |
| Chief Technology Officer | Steven Barnard (age 64) |
| President | Stephanie Campos |
| Chief Strategy & Corporate Development Officer | Jakob Wedel (age 53) |
Major Backers & Investors (ILMN)
Notable institutional backers of Illumina, Inc. include Capital Group, WCM Investment Management, LLC, AQR Capital Management, LLC, according to Nexqual as of June 9, 2026 at 22:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 10.28% |
| WCM Investment Management, LLC | 3.91% |
| AQR Capital Management, LLC | 2.63% |
| Corvex Management LP | 2.53% |
| AMERICAN BALANCED FUND | 2.37% |
| GROWTH FUND OF AMERICA | 2.29% |
| Sessa Capital IM, L.P. | 2.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.66% |
| BlackRock | 15.98% |
| State Street | 4.25% |
Source: Nexqual, June 9, 2026 at 22:41 UTC.
From Illumina, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
- The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.
- The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
Partnerships
- It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 616.18 | ▼ 3.03% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 445.77 | ▼ 0.24% |
| BIIB | Biogen Inc. | USD 199.1 | ▲ 1.92% |
| ISRG | Intuitive Surgical, Inc. | USD 426.61 | ▲ 1.08% |
| CRSP | CRISPR Therapeutics AG | USD 51.48 | ▼ 0.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:41 UTC. This page is informational and not investment advice.